Circulating endothelial cells (CECs) were evaluated by flow cytometry in immunodeficient mice bearing human lymphoma. A trend toward higher CEC values was observed on days 7 and 14 after transplant, and differences versus controls were highly significant on day 21 (P = 0.0061). A strong correlation was found between CEC and tumor volume (r, 0.942; P = 0.004) and between CEC and tumor-generated VEGF (r, 0.669; P = 0.02). In mice given cyclophosphamide, most of the circulating apoptotic cells were hematopoietic and not endothelial. Conversely, in mice given endostatin, all of the increase in apoptotic cells was in the endothelial cell compartment. CEC evaluation is promising as a noninvasive, surrogate angiogenesis marker.

Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma / S. Monestiroli, P. Mancuso, A. Burlini, G. Pruneri, C. Dell'Agnola, A. Gobbi, G. Martinelli, F. Bertolini. - In: CANCER RESEARCH. - ISSN 1538-7445. - 61:11(2001), pp. 4341-4344.

Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma

G. Pruneri;
2001

Abstract

Circulating endothelial cells (CECs) were evaluated by flow cytometry in immunodeficient mice bearing human lymphoma. A trend toward higher CEC values was observed on days 7 and 14 after transplant, and differences versus controls were highly significant on day 21 (P = 0.0061). A strong correlation was found between CEC and tumor volume (r, 0.942; P = 0.004) and between CEC and tumor-generated VEGF (r, 0.669; P = 0.02). In mice given cyclophosphamide, most of the circulating apoptotic cells were hematopoietic and not endothelial. Conversely, in mice given endostatin, all of the increase in apoptotic cells was in the endothelial cell compartment. CEC evaluation is promising as a noninvasive, surrogate angiogenesis marker.
non-Hodgkin-lymphoma; growth-factors; mouse model; cancer; chemotherapy; endostatin; predictor; drug
Settore MED/08 - Anatomia Patologica
Settore MED/15 - Malattie del Sangue
2001
Article (author)
File in questo prodotto:
File Dimensione Formato  
Monestiroli_Cancer Res_2001.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 149.38 kB
Formato Adobe PDF
149.38 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/457931
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 172
  • ???jsp.display-item.citation.isi??? 147
social impact